Isis Pharmaceuticals COO Sells $3,188,700 in Stock (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) COO B Lynne Parshall sold 90,000 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $35.43, for a total value of $3,188,700.00. Following the completion of the sale, the chief operating officer now directly owns 956 shares in the company, valued at approximately $33,871. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Goldman Sachs Group Inc. reiterated a “hold” rating on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note to investors on Monday. They now have a $26.00 price target on the stock. Separately, analysts at Needham & Company raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) to $46.00 in a research note to investors on Monday. They now have a “positive” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $23.00 to $27.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock.
Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $30.20.
Shares of Isis Pharmaceuticals (NASDAQ:ISIS) traded up 6.71% on Monday, hitting $38.48. The stock had a trading volume of 4,140,218 shares. Isis Pharmaceuticals has a one year low of $7.56 and a one year high of $39.83. The stock’s 50-day moving average is $28.60 and its 200-day moving average is $24.24. The company’s market cap is $4.437 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last announced its earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. On average, analysts predict that Isis Pharmaceuticals will post $-0.56 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.